Is FOX04-DRI legal in Arizona?
status · caveats apply
Preclinical 43-aa senolytic peptide; no human clinical trials registered; no FDA approval; pre-IND. No state-level peptide restrictions beyond federal law in Arizona.
category: no approval · last verified May 13, 2026
§ 01
Quick answer
Preclinical 43-aa senolytic peptide; no human clinical trials registered; no FDA approval; pre-IND. No state-level peptide restrictions beyond federal law in Arizona.
§ 02
Full status breakdown
Federal status
FDA approval
no approval
DEA scheduling
not scheduled
503A compounding
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: Pre-IND. FDCA §505 applies if marketed for human use.
Personal possession: Not federally criminalized.
Arizona — state-specific
Sport-body status
WADA 2026
USADA
unknown
NCAA
unknown
What we couldn’t verify
§ 03
Also known as
FOX04-DRI is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):
FOXO4-DRIFOXO4-D-Retro-Inversosenolytic peptideBaar et al. 2017 peptide
§ 04
Disclaimer
§ 05
Related
- Back to peptide legality lookup — pick a different compound or state
- Peptide pricing index — what each compound costs per mg across audited vendors
- Janoshik COA verifier — a separate question from legality: does the COA the vendor cites actually exist?
the roundup · monthly
Receipts in your inbox. Once a month.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.
14,200 subscribers· 0 sponsored items· 11 issues since launch